193 results on '"Shih, J-Y."'
Search Results
2. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
3. Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations
4. Recurrence of pericardial effusion after different procedure modalities in patients with non-small-cell lung cancer
5. Factors Influencing Unfavorable Outcomes in Cavitary Non-tuberculous Mycobacterial Pulmonary Disease (NTM-PD), With an Emphasis on Imaging Patterns: A Multicenter Cohort Investigation
6. EP12.02-07 The Effectiveness of Lorlatinib for Previously Treated ROS1-rearranged NSCLC: Real world Experience in Taiwan
7. Modelling of Ground-Borne Vibration When the Train Speed Approaches the Critical Speed
8. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
9. Numerical analysis of high-speed railway slab tracks using calibrated and validated 3D time-domain modelling
10. The Effect of TEOS Ratio and Calcination Temperature on Photoluminescence of Electrospun Luminescent Fibers
11. 91P Treatment (tx) patterns and outcomes in resectable early-stage non-small cell lung cancer (NSCLC): A global real-world (rw) study
12. PP01.31 Real-World Treatment Outcomes of Amivantamab in Pre-Approval Access (PAA) Participants with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations (ex20ins)
13. 302P Treatment patterns in resectable early-stage NSCLC in Taiwan: Subgroup analysis of a global real-world study
14. Dynamic Analysis of the Vehicle-Track-Bridge Interaction Using Vector Form Intrinsic Element Method
15. EP.07D.01 Regional Longitudinal Evaluation of Treatment Patterns in Early-Stage Non-Small Cell Lung Cancer (ELEVATE).
16. MA12.08 Preventing Infusion-Related Reactions with Intravenous Amivantamab: Primary Results from SKIPPirr, a Phase 2 Study.
17. EP08.02-151 A Real World Evidence of Lorlatinib for Taiwanese with advanced ALK Positive Non-Small Cell Lung Cancer
18. EP08.02-127 Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study
19. 1269P Preventing infusion-related reactions with intravenous amivantamab: Updated results from SKIPPirr, a phase II study
20. 55P The impact of liquid next-generation testing timing on treatment-naïve advanced non-small cell lung cancer: A prospective observational study
21. 12P A phase II study of atezolizumab in combination with bevacizumab, carboplatin or cisplatin, and pemetrexed for EGFR-mutant metastatic NSCLC patients after failure of EGFR TKIs
22. 35P Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)
23. 56P Simultaneous tissue and liquid next-generation sequencing after first-line EGFR tyrosine kinase inhibitors resistance in advanced non-small cell lung cancer
24. Polypropylene fiber reinforced concrete improved by using silica fume and acrylic emulsion polymer
25. Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs: 151P
26. 1217P EGFR TKIs in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG)
27. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer
28. Recurrence of Pericardial Effusion After Different Procedure Modalities in Patients with Non-Small Cell Lung Cancer (NSCLC)
29. Presence of Nontuberculous Mycobacteria in Respiratory Specimen Does Not Change the Outcome of Lung Cancer: A Retrospective Matched Cohort Study
30. A Novel IoT Based Positioning and Shadowing System for Dementia Training
31. RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: outcomes by EGFR mutation type
32. 116P Real-world outcomes of patients with metastatic non-small cell lung cancer receiving 2L+ atezolizumab-based treatments in Taiwan clinical practice
33. 146P The impact of prior immune checkpoint inhibitors or osimertinib treatment on NSCLC patients receiving atezolizumab treatment: A real-world observation
34. 145P UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations
35. A New Switch and Crossing Design: Introducing the Back to Back Bistable Switch
36. 399P Real-world insights into patients (pts) with advanced NSCLC and MET alterations
37. 29P Real-world data of atezolizumab in combination with bevacizumab, and platinum-based chemotherapy for EGFR-mutant metastatic non-small cell lung cancer patients after failure of EGFR tyrosine kinase inhibitors
38. Dynamic Analysis of the Vehicle-Track-Bridge Interaction Using Vector Form Intrinsic Element Method
39. P448Effects of left ventricular geometry on left atrial strain and strain rate in untreated hypertension
40. P320Role of post-systolic shortening of left ventricle for heart failure with preserved ejection fraction in untreated hypertension
41. 1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type
42. Treatment of Non-Small Cell Lung Cancer Patients in the Intensive Care Units with EGFR-Tyrosine Kinase Inhibitors
43. Large Cell Neuroendocrine Carcinoma of Lung: A Retrospective Cohort Study for Clinical Features and Treatment Effectiveness
44. 18F-Fluorodeoxyglucose Positron Emission Tomography for Assessment of Idiopathic Pulmonary Fibrosis Disease Activity and Prediction of Prognosis
45. Clinical Outcome and Benefit of Immune Checkpoint Inhibitors in Patients with Advanced Pulmonary Sarcomatoid Carcinoma
46. An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
47. Primary mediastinal large B-cell lymphoma mimicking liposarcoma
48. LBA11 Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis.
49. Digital infarcts showing microangiopathy in adult dermatomyositis suggest severe pulmonary involvement and poor prognosis
50. Tuberculous myositis: a rare but existing clinical entity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.